I-Corps: Nanomedicine as Treatment for Drug-Resistant Bacteria

I-Corps：纳米医学治疗耐药细菌

• 批准号: 1723667
• 负责人: Xiaoyang Xu
• 金额: $ 5万
• 依托单位: New Jersey Institute of Technology
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-01 至 2018-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1723667&HistoricalAwards=false
• 关键词: Corps; Nanomedicine; Treatment; Drug; Resistant

The broader impact/commercial potential of this I-Corps project is to treat an enormous healthcare danger, infections caused by drug resistance bacteria. The serious threat of drug resistant bacteria, including E. coli, MRSA and K. pneumonia, jeopardizes the health and wellbeing on a global population. Achievement of this development as well as commercializing the product will provide an effective way of delivering therapeutics to multidrug resistant bacteria infections, improving the life quality of patients worldwide. Global healthcare will be greatly improved, benefiting society and saving lives of many patients who currently suffer from drug resistant bacteria.This I-Corps project will produce an effective antibacterial drug delivery platform to combat multidrug resistant bacterial infections. Although numerous antimicrobial drugs have been developed with therapeutic efficacy, inefficient delivery is a significant issue due to the antibiotic resistance. An innovative nanomedicine approach is created to encapsulate current antimicrobial drugs in targeted nanoparticles to efficiently delivery drugs and combat the antibiotic resistance. This advanced technology will not only improve healthcare, but also enhance scientific and technological understanding of nanoparticle drug delivery systems in treating antibiotic resistance bacteria infections. This drug delivery system has great potential to advance knowledge as it may be altered to treat many other illnesses if successful.

这个I-Corps项目的更广泛的影响/商业潜力是治疗一个巨大的医疗保健危险，由耐药细菌引起的感染。包括大肠杆菌在内的耐药菌的严重威胁。coli、MRSA和K.肺炎，危及全球人口的健康和福祉。这一发展的实现以及该产品的商业化将提供一种有效的方法，为多重耐药细菌感染提供治疗，改善全球患者的生活质量。全球医疗保健将得到极大改善，造福社会，挽救许多目前遭受耐药细菌的患者的生命。I-Corps项目将产生一个有效的抗菌药物输送平台，以对抗多重耐药细菌感染。尽管已经开发了许多具有治疗功效的抗微生物药物，但由于抗生素耐药性，低效递送是一个重要问题。一种创新的纳米医学方法被创建来将当前的抗菌药物封装在靶向纳米颗粒中，以有效地递送药物并对抗抗生素耐药性。这项先进的技术不仅将改善医疗保健，而且还将提高对纳米颗粒药物递送系统在治疗抗生素耐药性细菌感染方面的科学和技术理解。这种药物输送系统有很大的潜力，以推进知识，因为它可能会改变，以治疗许多其他疾病，如果成功的。

项目成果

Dopant-Free Hydrogels with Intrinsic Photoluminescence and Biodegradable Properties

• DOI: 10.1002/adfm.201802607
• 发表时间: 2018-08-22
• 期刊: ADVANCED FUNCTIONAL MATERIALS
• 影响因子: 19
• 作者: Tsou, Yung-Hao;Zhang, Xue-Qing;Xu, Xiaoyang
• 通讯作者: Xu, Xiaoyang